Date: 2024-03-28
Authors:C. Cilliers1, P. McCloskey1, J. Morin2, J. Tran1; 1Mirati Therapeutics, 2Innovaderm Research.
Category: Other
Background: This phase I study evaluated the pharmacokinetics of adagrasib in subjects with mild, moderate, or severe hepatic impairment compared to subjects with normal hepatic function.